LAVAL, June 13 /PRNewswire-FirstCall/ - LAB International Inc. (TSX: LAB, Frankfurt: LD9.F, XETRA: LD9.DE) (“LAB”), an integrated drug development company with subsidiaries focused on developing therapies for the inhalation market and on providing contract research services, today announced enrollment of the first patients in its Fentanyl TAIFUN® Phase IIb clinical trial. Fentanyl TAIFUN® is a fast-acting Fentanyl formulation delivered using the Company’s TAIFUN® dry powder inhaler platform.
